Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines

Oncogene volume 26, pages 7163–7169 (2007)Cite this article

Abstract

Breast cancers that overexpress the ERBB2 tyrosine kinase receptor may be treated with the recombinant humanized monoclonal anti-ERBB2 antibody trastuzumab (herceptin). However, resistance to this targeted therapy is frequent. We have determined the response of 18 breast tumor cell lines to trastuzumab and compared it with the ERBB2 phosphorylation status using antibodies directed against tyrosine residue 1248. We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Adélaïde J, Huang HE, Murati A, Alsop AE, Orsetti B, Mozziconacci MJ et al. (2003). A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. Genes Chromosomes Cancer 37: 333–345.

    Article  Google Scholar 

  • Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S et al. (2005). Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24: 4540–4548.

    Article  CAS  Google Scholar 

  • Badache A, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A . (2004). Memo mediates ErbB2-driven cell motility. Nat Cell Biol 6: 515–522.

    Article  Google Scholar 

  • Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V et al. (2005). Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162–2171.

    Article  CAS  Google Scholar 

  • Baselga J, Gianni I, Geyer C, Perez EA, Riva A, Jackisch C . (2004). Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 31: 51–57.

    Article  CAS  Google Scholar 

  • Bernard-Marty C, Lebrun F, Awada A, Piccart MJ . (2006). Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 66: 1577–1591.

    Article  CAS  Google Scholar 

  • Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adélaïde J et al. (2004). Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 23: 2564–2575.

    Article  CAS  Google Scholar 

  • Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H et al. (2000). ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol 2: 407–414.

    Article  CAS  Google Scholar 

  • Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N et al. (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273–2284.

    Article  CAS  Google Scholar 

  • Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756–760.

    Article  CAS  Google Scholar 

  • Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648.

    Article  CAS  Google Scholar 

  • Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G . (2005). Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304: 604–619.

    Article  CAS  Google Scholar 

  • Emens LA . (2005). Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 12: 243–253.

    PubMed  Google Scholar 

  • Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL . (1993). Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res 53: 627–635.

    CAS  PubMed  Google Scholar 

  • Ghatak S, Misra S, Toole BP . (2005). Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 280: 8875–8883.

    Article  CAS  Google Scholar 

  • Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ . (2006). Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11: 857–867.

    Article  CAS  Google Scholar 

  • Hudelist G, Kostler WJ, Czerwenka K, Kubista E, Attems J, Muller R et al. (2006). Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer 118: 1126–1134.

    Article  CAS  Google Scholar 

  • Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, Elkahloun A et al. (2004). Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 23: 1010–1013.

    Article  CAS  Google Scholar 

  • Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630–1639.

    Article  CAS  Google Scholar 

  • Lacroix M, Leclercq G . (2004). Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249–289.

    Article  CAS  Google Scholar 

  • Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP et al. (2006). Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12: 57–61.

    Article  CAS  Google Scholar 

  • Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V et al. (2007). Frequency, prognosis impact and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12 and 20q13 amplifications in breast cancers. BMC Cancer 6: 245.

    Article  Google Scholar 

  • Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M et al. (2004). Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: 459–469.

    Article  CAS  Google Scholar 

  • Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin L et al. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274.

    Article  CAS  Google Scholar 

  • Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N et al. (2005). Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6: 240–246.

    Article  Google Scholar 

  • Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127.

    Article  CAS  Google Scholar 

  • Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J et al. (2005). Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473–482.

    CAS  PubMed  Google Scholar 

  • Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ . (2004). P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64: 3981–3986.

    Article  CAS  Google Scholar 

  • Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ . (2006). Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269–280.

    Article  CAS  Google Scholar 

  • Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515–527.

    Article  CAS  Google Scholar 

  • Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Ursule L et al. (2004). Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes. Cancer Res 64: 6453–6460.

    Article  CAS  Google Scholar 

  • Pegram M, Slamon DJ . (1999). Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26: 89–95.

    CAS  PubMed  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672.

    Article  CAS  Google Scholar 

  • Ramsauer VP, Carraway CA, Salas PJ, Carraway KL . (2003). Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem 278: 30142–30147.

    Article  CAS  Google Scholar 

  • Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684.

    Article  CAS  Google Scholar 

  • Tan-Chiu E, Yothers G, Romond E, Geyer Jr CE, Ewer M, Keefe D et al. (2005). Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin Oncol 23: 7811–7819.

    Article  CAS  Google Scholar 

  • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726.

    Article  CAS  Google Scholar 

  • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2001). First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61 (Suppl 2): 37–42.

    Article  CAS  Google Scholar 

  • Wobus M, Kuns R, Wolf C, Horn LC, Kohler U, Sheyn I et al. (2001). CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells. Gynecol Oncol 83: 227–234.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank O Segatto for the gift of the MCF7/ERBB2 cell line, S Ethier for the gift of the SUM cell lines and JM Durey for help with the illustrations. This work was supported by Inserm, Institut Paoli-Calmettes, Ligue Nationale Contre le Cancer (Label DB) and Institut National du Cancer (ACI2004-2006, PHRC24-04).

Author information

Author notes

  1. C Ginestier, J Adélaïde and A Gonçalvès: These authors contributed equally to this work.

Authors and Affiliations

  1. Département d'Oncologie Moléculaire, UMR599 Inserm, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France

    C Ginestier, J Adélaïde, L Repellini, F Sircoulomb, A Letessier, P Finetti, J Geneix, E Charafe-Jauffret, F Bertucci, J Jacquemier & D Birnbaum

  2. Département d'Oncologie Médicale, UMR599 Inserm, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France

    A Gonçalvès, F Bertucci & P Viens

  3. Faculté de Médecine, Université de la Méditerranée, Marseille, France

    A Gonçalvès, E Charafe-Jauffret, F Bertucci & P Viens

  4. Département de BioPathologie, Institut Paoli-Calmettes, Marseille, France

    E Charafe-Jauffret & J Jacquemier

Authors
  1. C Ginestier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Adélaïde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Gonçalvès
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Repellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Sircoulomb
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Letessier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Finetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Geneix
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Charafe-Jauffret
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F Bertucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Jacquemier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P Viens
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D Birnbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Birnbaum.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ginestier, C., Adélaïde, J., Gonçalvès, A. et al. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26, 7163–7169 (2007). https://doi.org/10.1038/sj.onc.1210528

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210528

Keywords

This article is cited by

Search

Advanced search

Quick links